ArticleJournal of pharmaceutical policy and practice2016
Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy.
Article in Journal of pharmaceutical policy and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Post-market surveillance of antiretroviral drug quality in Tanzania in the context of rising HIV drug resistance.Scientific reports · 2026Article
- Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity.PLOS global public health · 2026Article
- Quality of antidiabetic medicines in 13 sub-Saharan African countries: a cross-sectional survey.EClinicalMedicine · 2025Article
- Perceptions and practices on substandard and falsified medicines in humans and animals in Wakiso district, Uganda: A qualitative study.PloS one · 2025Article
- A high-performance thin-layer chromatography densitometric method for the separation of isomeric ceftriaxone in powder for injection formulation.Scientific reports · 2024Article
- Cost-effective track and trace technology for poor-quality chemotherapeutic pharmaceuticals in resource-limited countries: a review of the Chemotherapeutic Paper Analytical Device.Frontiers in medical technology · 2024Review
- Radio frequency identification technology; A method of analysis of falsified pharmaceutical products: Literature review.SAGE open medicine · 2024Review
- The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities.Journal of pharmaceutical policy and practice · 2023Article
- Quality of medicines in Sri Lanka: a retrospective review of safety alerts.BMC health services research · 2023Article
- Revisiting the issue of access to medicines in Africa: Challenges and recommendations.Public health challenges · 2022Review
- How the concept of WHO-listed authorities will change international procurement policies for medicines.BMJ global health · 2022Article
- Elusive quality: the challenges and ethical dilemmas faced by international non-governmental organisations in sourcing quality assured medical products.BMJ global health · 2021Review
- The Need for Ongoing Antimicrobial Stewardship during the COVID-19 Pandemic and Actionable Recommendations.Antibiotics (Basel, Switzerland) · 2020Article
- A survey of nongovernmental organizations on their use of WHO's prequalification programme.Bulletin of the World Health Organization · 2020Article
- The importance of visual inspection in national quality assurance systems for medicines.Journal of pharmaceutical policy and practice · 2020Article
- Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014.International journal of environmental research and public health · 2019Article
- Article
- The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists.BMJ global health · 2019Article
- The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs.Journal of pharmaceutical policy and practice · 2018Article
- Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.BMJ global health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly "involved" with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.